Diligence memo · auto-generated · as of July 2, 2026

149 Medical, Inc.

149 Medical, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

149 Medical, Inc. operates in Biotechnology, based in Worcester.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

149 Medical, Inc. has raised $450K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $250K on 2021-03-26.

Most recent recorded round closed around 2021-03-26.

Valuation (modeled)modeled

Provath models 149 Medical, Inc. at approximately $8.8M (range $133K–$80M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.56× the median modeled value of Pre-Seed Biotechnology companies in 2019–2021 (156 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 19 months.

Last raise 5.3 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.3× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 9% of Biotechnology peers (4293 compared).

Modeled value ranks above 17% of those peers.

Closest niche peers: Crimson BioPharm Inc., Pinpoint Therapeutics Inc., Transplant Logistics & Informatics Llc, RNAissance AG LLC, Pylum Biosciences, Inc..

Peoplefiled

4 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.